Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs

Alexis M Roth; Tyler S Bartholomew; Kathleen M Ward; Allison Groves; Silvana Mazzella; Scarlett Bellamy; K Rivet Amico; Adam W Carrico; Gail Ironson; Douglas Krakower

doi:10.1093/cid/ciae450

Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs

Clin Infect Dis. 2024 Sep 30:ciae450. doi: 10.1093/cid/ciae450. Online ahead of print.

Authors

Affiliations

¹ Department of Community Health and Prevention, Drexel University, Dornsife School of Public Health, Philadelphia, Pennsylvania, USA.
² Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.
³ Prevention Point Philadelphia, Philadelphia, Pennsylvania, USA.
⁴ Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
⁵ Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
⁶ Department of Health Promotion and Disease Prevention, Florida International University, Robert Stempel College of Public Health and Social Work, Miami, Florida, USA.
⁷ Department of Psychology, University of Miami, Miami, Florida, USA.
⁸ Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.
⁹ Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

PMID: 39347705
DOI: 10.1093/cid/ciae450

Abstract

Fifty-five of 62 women who inject drugs (WWID) selected long-acting cabotegravir (CAB-LA) over oral PrEP, and 51/55 received a first injection. More recent injection drug use and number of sexual partners were associated with selecting CAB-LA (P < .05). Findings provide preliminary evidence of a strong preference for longer-acting products among WWID.

Keywords: HIV prevention; long-acting injectable cabotegravir; pre-exposure prophylaxis; women who inject drugs.

Abstract

Grants and funding